Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer TLR-9 Adjuvant With Prevnar In HIV Patients Hints At Post-Wyeth Vaccine Opportunities

This article was originally published in The Pink Sheet Daily

Executive Summary

Danish academic trial has been looking at how Pfizer/Coley adjuvant can enhance effect of standard Wyeth Prevnar formulation.

You may also be interested in...

FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Narrows Population

The firm is hoping to gain licensure for chronic kidney disease patients first, and eventually to expand the indication to the broader hepatitis B vaccination population.

A Goliath Grows: Pfizer Buys Wyeth For $68 Billion

Merger propels Pfizer ahead in biotechnology and paves the way for the drug giant to navigate the loss of Lipitor in 2011.

Merck’s Heplisav Gets FDA Clinical Hold

Phase III subject diagnosed with Wegener’s granulomatosis, a rare blood vessel inflammation.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts